HLS Therapeutics Inc. (FRA:74D)

Market Cap	87.24M -3.7%
Revenue (ttm)	47.60M -1.9%
Net Income	-12.03M
EPS	-0.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303
Average Volume	n/a
Open	2.600
Previous Close	2.580
Day's Range	2.600 - 2.600
52-Week Range	2.280 - 3.420
Beta	n/a
RSI	45.66
Earnings Date	Mar 12, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Pharmaceutical Preparations
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 74D

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.

Financial numbers in USD